William Blair Issues Optimistic Outlook for NMRA Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at William Blair boosted their Q2 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Tuesday, May 13th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.35) per share for the quarter, up from their previous forecast of ($0.39). William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.39) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at $0.94 EPS.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02).

A number of other brokerages have also commented on NMRA. Stifel Nicolaus lowered Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $6.00 to $2.00 in a report on Friday, March 7th. Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. Bank of America reaffirmed an "underperform" rating and set a $1.00 price target (down from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd. Finally, Guggenheim downgraded shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, March 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Neumora Therapeutics has an average rating of "Hold" and an average target price of $9.29.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA traded up $0.03 during trading on Thursday, reaching $0.72. The stock had a trading volume of 324,683 shares, compared to its average volume of 2,461,381. Neumora Therapeutics has a one year low of $0.61 and a one year high of $17.19. The firm's 50 day moving average price is $0.83 and its two-hundred day moving average price is $4.17. The stock has a market cap of $116.30 million, a PE ratio of -0.38 and a beta of 2.96.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NMRA. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the 4th quarter valued at $61,000. PNC Financial Services Group Inc. acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at $64,000. Quantbot Technologies LP bought a new position in shares of Neumora Therapeutics in the fourth quarter valued at about $92,000. PEAK6 LLC bought a new stake in Neumora Therapeutics during the 4th quarter worth about $117,000. Finally, EntryPoint Capital LLC bought a new stake in Neumora Therapeutics during the 4th quarter worth about $135,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.